ClinicalTrials.gg
CompletedNCT04908579Updated Nov 2, 2026

Efficacy of Preventive Ketamine on Postoperative Pain

A Phase 4 interventional study of bupivacaine(intraperitoneally) and ketamine (intraperitoneally) and bupivacaine(intraperitoneally) and ketamine (intravenously) in Postoperative Pain, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Ain Shams University · Phase 4, Interventional, and Prevention

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
74th of 364
120 · median 70
Started
2021
with 30 others
Phase 4
133 of 364
18 open now
Registered
229th of 364
by date
Lead sponsor
8 of 364
Ain Shams University

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 74th largest by enrollment, is one of 31 that started in 2021, is one of 133 in phase 4, and was the 229th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

  • Although bariatric surgery is mainly performed laparoscopically, analgesic optimization is still essential to reduce complications and to improve the patients' comfort. In laparoscopic sleeve gastrectomy, the intraoperative peritoneal instillation of bupivacaine hydrochloride (30 ml, 0.25%) was known to be safe and effective in reducing postoperative pain, nausea, and vomiting.
  • Furthermore, usage of ketamine both as a pre and post-operative pain management is well established. Ketamine can be used solely or in combination with other co-adjuvant drugs, increasing their efficacy. Many therapeutic properties of ketamine have been attributed to its antagonism mechanism to N-Methyl-D-aspartate receptors.
03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - > 35 and \< 60 kg/m2
  • Either medically free or with well controlled hypertension and/or diabetes.

Exclusion criteria

Exclusion Criteria:

  • - Patient's refusal to participate in the study
  • > 60 kg/m2.
  • Age less than 21 years.
  • Patients with severe systemic disease which is not life-threatening.
  • Patients on antipsychotics, antidepressants and/or .
  • Patients with history of obstructive sleep apnea.
  • Allergic reaction to any of the study medications.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    - GROUP (I): 40 patients

    Drug: bupivacaine(intraperitoneally) and ketamine (intraperitoneally)

  • Active comparator
    - GROUP (II): 40 patients

    Drug: bupivacaine(intraperitoneally) and ketamine (intravenously)

  • Active comparator
    - GROUP (III) (Control): 40 patients

    Drug: bupivacaine(intraperitoneally)

Interventions

  • Drugbupivacaine(intraperitoneally) and ketamine (intraperitoneally)

    Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration 2. 10 ml normal saline 0.9% will be given intravenous.

  • Drugbupivacaine(intraperitoneally) and ketamine (intravenously)

    Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration 2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites.

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration 2. 10 ml normal saline 0.9% will be given intravenous.

06

What researchers measure

Primary outcomes

  1. Time to first given rescue analgesia(minutes)

    Time to first given rescue analgesia(minutes)

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Ain-Shams University Hospitals
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2026, 64 months.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 64 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jun 1, 2021
StartActual
Jun 15, 2021
Primary completionActual
Oct 28, 2026was Sep 2026
CompletionActual
Oct 28, 2026was Sep 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Sep 30, 2026→Oct 28, 2026 (actual)
Nov 2, 2026
Study completion
Sep 30, 2026→Oct 28, 2026 (actual)
Nov 2, 2026
Enrollment
90 (estimated)→120 (actual)
Nov 2, 2026
Interventions
Arm changed - GROUP (I): 30 patients→- GROUP (I): 40 patients; - GROUP (II): 30 patients→- GROUP (II): 40 patients; - GROUP (III) (Control): 30 patients→- GROUP (III) (Control): 40 patients
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2026→Oct 28, 2026 (now actual)
    Study completion Sep 30, 2026→Oct 28, 2026 (now actual)
    Enrollment 90 (estimated)→120 (actual)
    Interventions Arm changed - GROUP (I): 30 patients→- GROUP (I): 40 patients; - GROUP (II): 30 patients→- GROUP (II): 40 patients; - GROUP (III) (Control): 30 patients→- GROUP (III) (Control): 40 patients
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04908579
Responsible party
Ibrahim Mamdouh Esmat (Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt., Ain Shams University) — Principal investigator
First posted
Jun 1, 2021
Start date
Jun 15, 2021
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Ketamine

Start the discussion